Clinical trial · no report yet · Phase 1/Phase 2
NCT06800313
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- NCT06800313 ↗
- Recruiting
- Janssen Research & Development, LLC
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- Phase 1/2 Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
- Phase
- Phase 1/Phase 2
- Status
- Recruiting
- Conditions
- Metastatic Prostate Cancer
- Interventions
- JNJ-101556143 Formulation 1; JNJ-101556143 Formulation 2; JNJ-101556143 Formulation 3
- Arms
- JNJ-101556143 Phase 1 Part 1 - Dose Escalation · Experimental
- JNJ-101556143 Phase 1 Part 2 - Formulation Exploration · Experimental
- JNJ-101556143 Phase 2 Part 1 - Dose Optimization · Experimental
- Phase 2 Part 2A - SOAR · Experimental
- Phase 2 Part 2B - HSPC Expansion · Experimental
- Phase 2 Part 2C - HSPC Expansion · Experimental
- Phase 2 Part 2D - HSPC Expansion · Experimental
- Enrollment
- 190 (estimated)
- Primary outcomes
- Frequency of dose-limiting toxicities (DLTs)
- Frequency and severity of AEs and abnormal ECG, laboratory and clinical changes since baseline
- Phase 1 Part 2 (formulation exploration) relative bioavailability
- Sponsor
- Janssen Research & Development, LLC
- Start
- Feb 6, 2025
- Primary completion
- Aug 17, 2028 (estimated)
- Results posted
- No
- Registry record
- NCT06800313 · updated Sep 25, 2026